Check patentability & draft patents in minutes with Patsnap Eureka AI!

Use of stat1 in the treatment of paclitaxel-resistant epithelial ovarian cancer

A paclitaxel and ovarian cancer technology, applied in the field of biomedicine, can solve the problems such as STAT1 has not been reported, and achieve the effect of novel guiding concept, good application prospect and pressure reduction

Active Publication Date: 2021-11-16
JINSHAN HOSPITAL FUDAN UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] However, there is no report about the use of STAT1 of the present invention in the treatment of paclitaxel-resistant epithelial ovarian cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of stat1 in the treatment of paclitaxel-resistant epithelial ovarian cancer
  • Use of stat1 in the treatment of paclitaxel-resistant epithelial ovarian cancer
  • Use of stat1 in the treatment of paclitaxel-resistant epithelial ovarian cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1 Construction of monoclonal paclitaxel-resistant epithelial ovarian cancer cell line

[0024] Build method:

[0025] Prepare human epithelial ovarian cancer cell line OVCAR-3 (USA, American Type Culture Collection Bank), paclitaxel (China, Sichuan Taiji Pharmaceutical Co., Ltd.). OVCAR-3 cell line is sensitive to paclitaxel, paclitaxel-resistant epithelial ovarian cancer cell line was constructed from OVCAR-3 cell line, the method is as follows:

[0026] (1) OVCAR-3 cells were inoculated into T25 culture flasks at a density of 30%, and cultured in RPMI-1640 (Sigma, USA) complete medium containing 10% fetal bovine serum (Gibco, USA). After 24 hours, the medium was discarded, washed with phosphate buffer, replaced with a complete medium containing 0.01 μM paclitaxel, and cultured for 24 hours. Then the culture medium was discarded, rinsed with phosphate buffered saline, replaced with paclitaxel-free complete medium for 3-5 days, and then replaced with 0.01 μM p...

Embodiment 2

[0029] Example 2 Construction of STAT1 function loss model

[0030] 1 Experimental method

[0031] 1.1 Cell culture

[0032] The cells used without special emphasis were cultured in culture plates or flasks using RPMI-1640 medium supplemented with 10% fetal bovine serum.

[0033] 1.2 Transfection of siRNA

[0034] Synthesized siRNA (synthesized by Shanghai Gemma Company) was shipped in the form of dry powder. Dissolve the dry powder with a certain volume of sterile DEPC water (supplied) to make a 20μM solution. The siRNA sequence is shown in Table 1:

[0035] Table 1

[0036]

[0037] Prepare well-grown cells to be treated, and transfect when the cells reach a suitable density. Firstly, 2 ml of Opti-MEM medium (USA, Gibco Company) was replaced in each well, and then an appropriate volume of transfection complex was prepared according to the needs of the experiment, and the transfection complex was added dropwise to each well in turn. For each well of a six-well plate...

Embodiment 3

[0043] Example 3 Construction of STAT1 function acquisition model

[0044] 1 Experimental method

[0045] 1.1 Cell culture

[0046]The cells used without special emphasis were cultured in culture plates or flasks using RPMI-1640 medium supplemented with 10% fetal bovine serum.

[0047] 1.2 Plasmid transfection

[0048] The structure of the STAT1 overexpression plasmid vector used is as follows: image 3 As shown, it was synthesized by Suzhou Jinweizhi Biotechnology Co., Ltd., and DH5α Escherichia coli containing the plasmid vector was prepared.

[0049] When performing transfection experiments, first recover the DH5α Escherichia coli containing the STAT1 overexpression plasmid, and use the plasmid endotoxin-free plasmid mini-prep kit (China, Beijing Tiangen Company) for plasmid extraction. After obtaining the plasmid, configure it to 500ng / μl for use.

[0050] Prepare well-grown cells to be treated, and transfect when the cells reach a suitable density. Firstly, 2 ml of ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of biomedicine, specifically, the use of STAT1 in the treatment of paclitaxel-resistant epithelial ovarian cancer. The present invention constructed a monoclonal paclitaxel-resistant epithelial ovarian cancer cell line and constructed a STAT1 function loss model by transfecting siRNA. It was found that after the expression of STAT1 decreased, the expression levels of tumor stem cell-related markers in the cells increased, suggesting that STAT1 has a relationship with stemness. There is a negative regulatory relationship between them; the STAT1 function acquisition model was constructed by transfecting the STAT1 overexpression plasmid, and it was found that after the expression of STAT1 increased, the expression levels of tumor stem cell-related markers in the cells decreased, and the sphere-forming ability of the cells decreased, indicating that overexpression STAT1 can inhibit the stemness of drug-resistant cells. And the colony formation ability and proliferation growth ability of the cells also decreased, indicating that overexpression of STAT1 can inhibit the growth and proliferation of paclitaxel-resistant epithelial ovarian cancer cells.

Description

technical field [0001] The invention relates to the technical field of biomedicine, specifically, the use of STAT1 in the treatment of paclitaxel-resistant epithelial ovarian cancer. Background technique [0002] The incidence of ovarian cancer ranks third among female reproductive system malignancies, and it is also the most lethal gynecological tumor. The most common pathological type of ovarian cancer is epithelial ovarian cancer, and the current standard first-line treatment is tumor-reductive surgery combined with platinum-paclitaxel chemotherapy. [0003] Patients can obtain more obvious effects in the initial stage of treatment, and the remission rate of the initial treatment is high, but most patients relapse after two years of complete remission, and the relapse rate is as high as 80%. Recurrent epithelial ovarian cancer is resistant to almost all chemotherapy drugs, which greatly limits the clinical efficacy and application range of chemotherapy, and is also the m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61P35/00
CPCA61K45/00A61P35/00
Inventor 许国雄王繁晨
Owner JINSHAN HOSPITAL FUDAN UNIV
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com